PREVAIL THERAPEUTICS
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
PREVAIL THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2017-01-01
Status:
Active
Contact:
917-336-9310
Email Addresses:
[email protected]
Total Funding:
129 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network Font Awesome
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Aopia Biosciences
Aopia Biosciences is a biotechnology business focused on developing cutting-edge bioengineering solutions and technologies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
E-Health Now LLC
We are the first HIPAA compliant platform that focuses on optimizing cancer treatment plans for patients in China locally, on a B2B model.
GPS Dental
GPS Dental is a Dental Service Organization that provides care to communities through philanthropic service.
Modis Therapeutics
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
EcoR1 Capital
EcoR1 Capital investment in Series B - Prevail Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Prevail Therapeutics
Adage Capital Management
Adage Capital Management investment in Series B - Prevail Therapeutics
OrbiMed
OrbiMed investment in Series B - Prevail Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Prevail Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Series B - Prevail Therapeutics
Pontifax
Pontifax investment in Series B - Prevail Therapeutics
Omega Funds
Omega Funds investment in Series B - Prevail Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Prevail Therapeutics
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series B - Prevail Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-05-17 | Scribe Therapeutics | Prevail Therapeutics investment in Convertible Note - Scribe Therapeutics | N/A |
More informations about "Prevail Therapeutics"
About Us - Prevail Therapeutics
At Prevail, we are developing gene therapies designed to slow or stop the underlying causes of neurodegenerative and rare diseases Learn more about our clinical researchSee details»
Prevail Therapeutics - LinkedIn
Sep 23, 2024 At Prevail Therapeutics, we are developing novel gene therapies that target the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Our mission is to translate ...See details»
Prevail Therapeutics - Crunchbase Company Profile
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.See details»
Prevail Therapeutics - 2025 Company Profile & Team - Tracxn
Explore Prevail Therapeutics' in-depth company profile, including funding details, key investors, leadership, and competitors.See details»
Prevail Therapeutics 2025 Company Profile: Valuation, …
Information on acquisition, funding, cap tables, investors, and executives for Prevail Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Prevail Therapeutics Inc Company Profile - Overview
Prevail Therapeutics Inc (Prevail Therapeutics), a subsidiary of Eli Lilly and Co, is a biotechnology company. It primarily focuses on developing gene therapies for patients with parkinson’s …See details»
Prevail Therapeutics - Overview, News & Similar companies
Apr 23, 2024 A front-line source in Artificial Intelligence has indicated that the organization is in the midst of initiatives related to conversational intelligence. Prevail Therapeutics Inc is …See details»
Prevail Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
May 7, 2025 Explore Prevail Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 76 news, and 1 literature, Disease Domain:Nervous ...See details»
Company: Prevail Therapeutics - CRISPR Medicine
Prevail Therapeutics, a fully owned subsidiary of Eli Lilly, is leveraging adeno-associated virus serotype 9 (AAV9) to deliver gene therapeutics to address devastating neurogenerative …See details»
Prevail Therapeutics Inc. - AnnualReports.com
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases.See details»
Organization | Prevail Therapeutics
Prevail Therapeutics Report issue For profit Phase 1 Phase 2 Founded: New York NY United States (2017) Status: Acquired by Eli Lilly (2020) Organization Overview First Clinical Trial …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to …See details»
Prevail Therapeutics | Gaucher Community Alliance
Prevail Therapeutics is leading a new era of gene therapy-based treatments with the potential to slow or stop the progression of neurodegenerative diseases, including Gaucher disease and …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics
Dec 15, 2020 Lilly Announces Agreement to Acquire Prevail Therapeutics Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience …See details»
Brochure-2023 - Prevail
At Prevail, we are researching adeno-associated virus or AAV-based gene therapy, which relies on a modified virus (also called a “vector”) to transport genetic material to specific cells in the …See details»
prevailtherapeutics.com
About Prevail At Prevail, we are leading a new era of gene therapy-based treatments with the potential to slow or stop the progression of neurodegenerative diseases, including genetic …See details»
Cardiovascular Outcome Study to Evaluate the Effect of …
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to evaluate the effect of 10mg Obicetrapib in participants with Atherosclerotic Cardiovascular Disease …See details»
Global Healthcare Firm Eli Lilly Completes Acquisition of Prevail ...
Jan 22, 2021 NEW YORK, USA – NYSE-listed Eli Lilly and Company announced the successful completion of its acquisition of gene therapies firm Prevail Therapeutics. The acquisition …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics
Dec 15, 2020 About Prevail Therapeutics Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease …See details»
Prevail Therapeutics - Financial Details - Crunchbase
Jun 20, 2019 Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.See details»